Adding nimotuzumab to post-surgery adjuvant cisplatin-based chemoradiotherapy does not improve survival outcomes in patients with HNSCC.

Tiragolumab plus atezolizumab does not improve survival compared to durvalumab in locally advanced, unresectable, stage 3 NSCLC.

Data from a phase 1/2 study support the use of sevabertinib in patients with HER2-mutated NSCLC, an investigator says.

This article was originally published on Stateline. In a clear rebuke of recent federal health policy, 15 Democratic governors announced Wednesday they’ve formed a public health alliance that breaks ...

For patients with advanced or metastatic RCC, fruquintinib plus sintilimab improves PFS compared to investigator’s choice of axilitinib or everolimus.

In TNBC, pembrolizumab at a tenth of the current standard dose, plus chemotherapy, increased pCR compared to chemotherapy alone.

Regorafenib plus nivolumab did not improve survival over chemotherapy in patients with previously treated gastric/GEJ cancer.

Adding abemaciclib to endocrine therapy improved overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer.

Adding durvalumab to induction and maintenance with Bacillus Calmette–Guérin (BCG) can improve disease-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer, data ...

Prior authorization is placing a growing burden on radiation oncologists, leading to treatment delays and suboptimal treatment, and compromising patient safety, according to a survey presented at the ...

The researchers noted that the lack of an inflation adjustment in the MPFS has undermined the financial stability of oncology practices, increased reliance on drug reimbursement, and threatened access ...

Layoff notices to some 740 workers at the U.S. Centers for Disease Control and Prevention have been rescinded.